Greenwood Capital Associates LLC Sells 90,403 Shares of InfuSystem Holdings, Inc. (NYSE:INFU)

Greenwood Capital Associates LLC reduced its stake in shares of InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) by 89.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,443 shares of the company's stock after selling 90,403 shares during the period. Greenwood Capital Associates LLC's holdings in InfuSystem were worth $56,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of INFU. First Eagle Investment Management LLC boosted its position in InfuSystem by 25.9% during the fourth quarter. First Eagle Investment Management LLC now owns 908,371 shares of the company's stock valued at $7,676,000 after purchasing an additional 186,668 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of InfuSystem by 283.5% during the 4th quarter. JPMorgan Chase & Co. now owns 59,662 shares of the company's stock worth $504,000 after purchasing an additional 44,106 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of InfuSystem by 150.3% during the 4th quarter. Marshall Wace LLP now owns 53,315 shares of the company's stock valued at $451,000 after buying an additional 32,015 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of InfuSystem by 5.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 456,043 shares of the company's stock valued at $3,853,000 after buying an additional 21,697 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in InfuSystem in the fourth quarter worth approximately $164,000. 71.13% of the stock is owned by institutional investors and hedge funds.

InfuSystem Stock Performance

Shares of NYSE:INFU traded up $0.11 during trading on Friday, reaching $6.21. The stock had a trading volume of 129,455 shares, compared to its average volume of 98,994. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The stock has a fifty day simple moving average of $5.36 and a two-hundred day simple moving average of $6.83. The firm has a market capitalization of $130.51 million, a price-to-earnings ratio of 103.52 and a beta of 1.81. InfuSystem Holdings, Inc. has a 52 week low of $4.61 and a 52 week high of $9.97.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Sidoti upgraded shares of InfuSystem to a "strong-buy" rating in a research note on Tuesday, March 18th. Wall Street Zen lowered InfuSystem from a "strong-buy" rating to a "buy" rating in a report on Wednesday, May 14th. Finally, B. Riley upgraded InfuSystem to a "strong-buy" rating in a research note on Thursday, May 8th.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.